| 1 |
dpavlin |
1.3 |
<p align="center"><b>RESEARCH AND DEVELOPMENT</b></p> |
| 2 |
|
|
<p>PLIVA has a long and successful R&D track record that dates back to 1936. Its |
| 3 |
|
|
investments in R&D have grown to a decade high of USD 40 m and represent 10% |
| 4 |
|
|
of PLIVA's healthcare turnover. The strategic goal for this continued investment |
| 5 |
|
|
is to achieve a balanced portfolio for PLIVA's short, medium and long-term growth. |
| 6 |
|
|
Commitment to a unique two-fold R&D strategy: the discovery and development of new |
| 7 |
|
|
chemical entities and the development of value added generics, is further supported |
| 8 |
|
|
by PLIVA's licensing strategy.</p> |
| 9 |
|
|
<p>PLIVA has focused its expertise on NCE research, and through this "Smart Discovery Strategy" globally |
| 10 |
|
|
competitive results are expected. Research activities are focusing on the early |
| 11 |
|
|
phases of discovery and development only (i.e. Phase I/II clinical trials), |
| 12 |
|
|
while for advanced stages of development |
| 13 |
|
|
and marketing, strategic partnerships will be established. PLIVA's vision in |
| 14 |
|
|
research is to develop new drugs whose production will serve unmet medical needs |
| 15 |
|
|
and will have commercial returns in line with PLIVA's growth targets.</p> |
| 16 |
|
|
<p align="center"><img src="p/Superrnd_ljudi_4.jpg" width="300" height="198" border=1></p> |
| 17 |
|
|
<p>In development, superior results will be achieved by the in-house development |
| 18 |
|
|
of new molecules, the development of final pharmaceutical Rx or OTC drug forms |
| 19 |
|
|
and the development of Fine Chemicals processes. PLIVA's Competitive Generic |
| 20 |
|
|
Strategy is based on decades of experience and expertise in new API development |
| 21 |
|
|
coupled with regular and successful FDA inspections as well as PLIVA's excellence |
| 22 |
|
|
in chemistry and the innovative improvement of existing drugs.</p> |
| 23 |
|
|
<p>Our R&D strategy binds together a top quality international research team, |
| 24 |
|
|
a network of strategic partnerships with multinational and biotech companies |
| 25 |
|
|
and a broad cooperation with various international universities and institutes. |
| 26 |
|
|
These activities are further supported by an independent body that consists |
| 27 |
|
|
of leading experts in the R&D areas of interest to PLIVA - PLIVA's International |
| 28 |
|
|
Scientific Advisory Board.</p> |
Parent Directory
| 
Revision Log